Allen Hord, MD
Interventional Pain Medicine · Atlanta, GANPI 1801845409
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 303 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 50 manufacturers, the largest accounting for just 19.0% — the pattern of someone who eats at a lot of different presentations.
Across 303 payments — averaging $30.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nevro Corp.$2K
- Boston Scientific$944
- Forte Bio-pharma LLC$938
- Medtronic$874
- Collegium Pharmaceutical, Inc.$649
- Abbott$592
- plus $4K from 44 others
What the payments were for
- Food & beverage$9,273100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prolate$1,362
- Senza Spinal Cord Stimulation System$557
- Omnia$485
- INTELLIS ADAPTIVESTIM$381
- Nalocet$368
- Intracept$261
- mild Device Kit$172
- PROCLAIM$157
- BIOTRONIK$147
- RESTORE$133
- WaveWriter Alpha Prime 16$132
- Proclaim XR IPG$124
- Zilretta$122
- GENERAL PAIN MANAGEMENT$113
- AIMOVIG$108
- TANLOR$108
How this compares
$9,273 in reported general payments places this provider in the 70th percentile of 129 interventional pain medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProlateOxycodone Hcl/Acetaminophen | 12 | $50,641 |
| OxycontinOxycodone Hcl | 41 | $45,021 |
| BelbucaBuprenorphine Hcl | 42 | $32,441 |
| Fentanyl | 122 | $18,242 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 574 | $18,232 |
| Oxycodone Hcl | 565 | $17,499 |
| Xtampza ErOxycodone Myristate | 29 | $14,119 |
| Buprenorphine | 47 | $11,924 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 415 | $9,373 |
| MovantikNaloxegol Oxalate | 20 | $8,170 |
| LinzessLinaclotide | 15 | $7,826 |
| Morphine Sulfate ErMorphine Sulfate | 189 | $7,105 |
| Pregabalin | 139 | $3,200 |
| Gabapentin | 182 | $2,664 |
| Hydromorphone Hcl | 117 | $2,262 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Forte Bio-pharma LLCProlate | $938 | $50,64112 claims |
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er | $649 | $46,56071 claims |
| Redhill Biopharma Inc.Movantik | $74 | $8,17020 claims |
| AbbVieLinzess | $163 | $7,82615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 129 interventional pain medicine providers in Georgia.
Other interventional pain medicine in Atlanta
- Alexandra MoreiraAtlanta$79K
- Logan BurgessAtlanta$11K
- Mayson CallawayAtlanta$9K
- Jignesh GandhiAtlanta$8K
- Pickens PattersonAtlanta$6K
- Naureen AdamAtlanta$6K
- Shawn CableAtlanta$5K
- Emmanuel GageBrunswick$602K
- Jordan TateJasper$540K
- Christopher BovinetBrunswick$338K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.